With regard to government involvement in the negotiations with Vertex Pharmaceuticals for a Price Listing Agreement with the Pan Canadian Pharmaceutical Alliance, in relation to cystic fibrosis treatments: (a) what is the current status of the negotiations; (b) what specific measures, if any, has the government taken to ensure that Kalydeco and Orkambi are available to all Canadians that require the medication; (c) has the government taken any specific measures to make Trikafta available to Canadians; and (d) how many months, or years, will it be before the government finishes the regulatory and review process related to the approval of Trikafta?
In the House of Commons on November 16th, 2020. See this statement in context.